The biotech got a little help from Amazon's AWS.
Don't be surprised it it does.
Mobeewave's technology could transform every iPhone into a mobile payment terminal.
The shares have surged in the triple digits since the start of the year. And additional gains may be on the horizon.
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
If and when mRNA-1273 becomes available, it will apparently be relatively expensive.